Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$7.26 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
11.35 million
Earnings per share
-3.236
Dividend per share
N/A
Year To Date Return
-22.22%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News
⏸️ Investing
The horror: Pot stocks collapse 30% in a month
⏸️ Investing
Why these 4 ASX shares have started the week deep in the red
⏸️ Investing
Aussie pot stock update: Here's what you missed this month
⏸️ Investing
Pot stocks are not winning any brownie points
⏸️ Investing
Pot stocks start the week strongly: Here's what you need to know
⏸️ Investing
Put your life savings in pot stocks – but first, read this
⏸️ Investing
Aussie pot stocks storm higher: Here's what you need to know
⏸️ Investing
Why these 4 ASX shares have rocketed higher today
⏸️ Investing
Pot stocks CRUSHED: Here's what you need to know
⏸️ Investing
S&P/ASX 200 finishes higher Monday: 8 shares you missed
⏸️ Investing
Here's why these 4 ASX shares have started the week with a BANG
⏸️ Investing
Why these 4 shares are getting slammed on Friday
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
ZLD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 21 Nov 2024 | $0.64 | $-0.01 | -1.54% | 12,105 | $0.66 | $0.66 | $0.64 |
| 20 Nov 2024 | $0.65 | $-0.01 | -1.52% | 848 | $0.70 | $0.70 | $0.65 |
| 19 Nov 2024 | $0.66 | $0.00 | 0.00% | 1,086 | $0.66 | $0.66 | $0.66 |
| 18 Nov 2024 | $0.66 | $0.00 | 0.00% | 2,218 | $0.66 | $0.66 | $0.66 |
| 15 Nov 2024 | $0.66 | $-0.04 | -5.71% | 641 | $0.70 | $0.72 | $0.66 |
| 14 Nov 2024 | $0.70 | $0.00 | 0.00% | 471 | $0.70 | $0.70 | $0.70 |
| 13 Nov 2024 | $0.70 | $0.00 | 0.00% | 9 | $0.70 | $0.70 | $0.70 |
| 12 Nov 2024 | $0.70 | $0.04 | 6.06% | 544 | $0.66 | $0.70 | $0.66 |
| 11 Nov 2024 | $0.66 | $-0.04 | -5.71% | 3,703 | $0.70 | $0.70 | $0.66 |
| 08 Nov 2024 | $0.70 | $-0.05 | -6.67% | 2,567 | $0.75 | $0.75 | $0.70 |
| 07 Nov 2024 | $0.75 | $0.00 | 0.00% | 158 | $0.75 | $0.75 | $0.75 |
| 06 Nov 2024 | $0.75 | $0.01 | 1.35% | 2,042 | $0.74 | $0.78 | $0.74 |
| 05 Nov 2024 | $0.74 | $0.03 | 4.23% | 5,369 | $0.74 | $0.78 | $0.74 |
| 04 Nov 2024 | $0.71 | $0.01 | 1.43% | 4,939 | $0.67 | $0.71 | $0.66 |
| 31 Oct 2024 | $0.70 | $0.02 | 2.96% | 3,066 | $0.67 | $0.73 | $0.66 |
| 30 Oct 2024 | $0.68 | $-0.05 | -6.90% | 3,874 | $0.73 | $0.73 | $0.68 |
| 29 Oct 2024 | $0.73 | $-0.01 | -1.36% | 8,831 | $0.74 | $0.76 | $0.73 |
| 28 Oct 2024 | $0.74 | $-0.10 | -12.05% | 34,192 | $0.82 | $0.82 | $0.66 |
| 25 Oct 2024 | $0.83 | $-0.05 | -5.68% | 3,602 | $0.88 | $0.90 | $0.82 |
| 24 Oct 2024 | $0.88 | $-0.01 | -1.13% | 1,549 | $0.89 | $0.89 | $0.88 |
| 23 Oct 2024 | $0.89 | $0.01 | 1.14% | 1,018 | $0.88 | $0.89 | $0.88 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Nov 2023 | Timothy (Tim) Slate | Issued | 100,000 | $47,335 |
Director remuneration.
|
| 24 Nov 2023 | Oludare Odumosu | Issued | 200,000 | $94,669 |
Director remuneration. As per announcement on 24-11-2023
|
| 24 Nov 2023 | Osagie Imasogie | Issued | 150,000 | $71,002 |
Director remuneration.
|
| 24 Nov 2023 | Greg Blake | Issued | 175,000 | $82,836 |
Director remuneration.
|
| 24 Nov 2023 | Donna O'Donnell | Issued | 145,000 | $91,430 |
Director remuneration.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate provides accounting and secretarial advice to private and public companies. Mr Slate has over 15 years of experience in chartered accounting.
|
| Dr Oludare Odumosu | Managing Director | Dec 2019 |
Dr Odumosu has over 10 years of experience in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a unique combination of experiences from several academic, public health and life science organisations.
|
| Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualised and established GlaxoSmithKline Ventures and was its founding Vice President.
|
| Mr Greg Blake | Executive Director | Feb 2023 |
Mr Blake has led the strategic development and commercialisation of a number of products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a solid foundation of knowledge across marketing and the entire commercial value chain.
|
| Dr Donna Gentile O'Donnell | Non-Executive Director | Jun 2023 |
Dr O'Donnell has led a diverse and successful career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organisations, universities, and life science companies, including Cephalon Pharmaceuticals.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malik Majeed | 1,134,644 | 10.00% |
| Quincy Street Capital Llc | 456,622 | 4.02% |
| Sharri J Rochlin <Rochlin Family Resource A/C> | 393,168 | 3.46% |
| Mr Zoltan Kerekes | 393,168 | 3.46% |
| Osagie Imasogie | 393,168 | 3.46% |
| Sunset Capital Management Pty Ltd <Sunset Superfund A/C> | 383,725 | 3.38% |
| Ms Lisa Gray | 381,988 | 3.37% |
| Mera I Llc\C | 332,479 | 2.93% |
| Muller Ct Pty Ltd <Muller Super Fund A/C> | 312,126 | 2.75% |
| Mr Torsten M Geers <The Torsten M Geers Living A/C> | 307,454 | 2.71% |
| Mr Steve Shapiro | 302,571 | 2.67% |
| Mara Gordon | 252,242 | 2.22% |
| Mr Saul Shorr and Mrs Margaret Shorr | 151,285 | 1.33% |
| Dr Chanda Latrice Macias | 146,479 | 1.29% |
| Mera Ii Llc\C | 133,372 | 1.18% |
| Oludare Odumosu | 131,766 | 1.16% |
| Citicorp Nominees Pty Limited | 128,727 | 1.13% |
| Mr Daniel Hexter and Mrs Shannon Hexter | 103,389 | 0.91% |
| Geers Egag Llc | 85,715 | 0.76% |
| Connie H Katz and Samuel P Katz | 78,063 | 0.69% |
